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The extent that age-dependent mitochondrial dysfunction drives neurodegeneration is not well understood. This
study tested the hypothesis that mitochondria contribute to spinal cord injury (SCI)-induced neurodegeneration
in an age-dependent manner by using 2,4-dinitrophenol (DNP) to uncouple electron transport, thereby increasing
cellular respiration and reducing reactive oxygen species (ROS) production. We directly compared the effects of
graded DNP doses in 4- and 14-month-old (MO) SCI-mice and found DNP to have increased efficacy in mito
chondria isolated from 14-MO animals. In vivo, all DNP doses significantly exacerbated 4-MO SCI neuro
degeneration coincident with worsened recovery. In contrast, low DNP doses (1.0-mg/kg/day) improved tissue
sparing, reduced ROS-associated 3-nitrotyrosine (3-NT) accumulation, and improved anatomical and functional
recovery in 14-MO SCI-mice. By directly comparing the effects of DNP between ages we demonstrate that
mitochondrial contributions to neurodegeneration diverge with age after SCI. Collectively, our data indicate an
essential role of mitochondria in age-associated neurodegeneration.

1. Introduction
Metabolic processes shift throughout a lifespan as an inevitable
consequence of aging (a thorough review of how aging affects brain
metabolism can be found in Mattson and Arumugam (2018)). Under
lying many age-associated metabolic changes is a progressive deterio
ration in mitochondrial function (Gruber et al., 2013, 2008; Srivastava,
2017). Mitochondria are the primary producers of energy and play vital
roles in maintaining health and homeostasis of cellular functions. It is,
therefore, not surprising that mitochondrial dysfunction significantly
contributes to aging and disease progression (Gruber et al., 2008; Sri
vastava, 2017). Specifically, a biproduct of mitochondrial respiration is
the generation of reactive oxygen species (ROS), which under normal
physiological conditions function in vital cell signaling. In excess how
ever, increases in ROS drive pathophysiological processes such as pro
tein and lipid oxidation that can induce senescence and accelerate

disease pathology (Birla et al., 2020; Cherubini et al., 2020; Hall et al.,
2015; Ricke et al., 2020; Saxena et al., 2019; Zhang et al., 2019).
An increase in ROS production from mitochondria is a known
consequence of aging (Yonutas et al., 2015) and is further exacerbated
by several neurodegenerative or neurotraumatic conditions (Birla et al.,
2020; Cherubini et al., 2020; Pandya et al., 2007; Ricke et al., 2020).
One way ROS is generated by mitochondria is when resistance to elec
tron transfer increases, which induces slippage of electrons onto soluble
oxygen forming the free radical superoxide (Suski et al., 2012; Zhao
et al., 2019). Downstream reactive products of superoxide induce pre
dictable and detectable cellular damage to lipids (4-hydroxynonenol, 4HNE), proteins (3-Nitrotyrosine, 3-NT, when reacted with nitric oxide),
and DNA, all of which accumulate with age and disease. Consequently,
therapeutic strategies aimed at ameliorating mitochondrial dysfunction
have emerged as promising approaches to mitigate or slow neuro
degeneration occurring with age and disease or trauma (Caldeira da
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Silva et al., 2008; Yonutas et al., 2016). However, the extent to which
mitochondrial changes with age contribute to, or confound, neuro
degeneration and recovery is not well understood.
Increases in mitochondrial membrane potential are tightly associ
ated with increased resistance to electron flow and accelerated ROS
formation (Zhao et al., 2019). Under normal homeostatic conditions,
increased ROS generated by mitochondria induce feedback regulation of
mitochondrial regulatory proteins such as uncoupling proteins (UCPs)
(Ježek et al., 2015; Pecqueur et al., 2001). UCPs reduce mitochondrial
membrane potential, allowing flow of protons back into the mitochon
drial matrix, effectively decreasing respiratory resistance and mitigating
superoxide leak during electron transport (Zhao et al., 2019). Although
decreasing mitochondrial ROS may appear beneficial to cellular health,
increasing permeability of protons through the inner mitochondrial
membrane uncouples respiration from ATP production (Geisler et al.,
2016). In compromised environments such as in neurodegeneration or
neurotrauma, mitochondria are therefore engaged in a competing bal
ance to meet increased cellular energy demands while regulating ROS
over-production. How this homeostatic imbalance is regulated with age
in health and disease is not well understood. Based upon the potential
double-edged sword of pharmacological uncouplers, in the current study
we used the uncoupling agent 2,4-dinitrophenol (DNP) to study agedependent mitochondrial function after spinal cord injury (SCI).
Mitochondria that have been injured following SCI increase ROS
production which exacerbate neurodegeneration and tissue damage (Jin
et al., 2004; McEwen et al., 2011; Pandya et al., 2007; Patel et al., 2009).
This secondary injury after SCI can propagate for weeks-to-months
following the primary insult. Mitigating respiratory ROS production
immediately post-injury, or ROS generated from inflammatory nonmitochondrial derived sources, have proven effective and limits sec
ondary injury (Impellizzeri et al., 2011; Jin et al., 2004; Khayrullina
et al., 2015; Pandya et al., 2007; Patel et al., 2009; Zhang et al., 2019).
How mitochondria contribute to a progressive neurodegeneration
observed after SCI is less well understood, and almost nothing is known
about how age effects this process. A lack of knowledge about how aging
effects SCI is of growing concern as a shift in the average age at time of
SCI has progressed from 28 years of age to 42 since the 1970’s (NSCISC,
2013). The prominent role of mitochondria in both aging and SCI has
clinical implications since the efficacy of mitochondrial-based pharma
cotherapies for neurotrauma may vary with age. This study utilized the
progressive neurodegeneration occurring following SCI to interrogate
how age affects mitochondrial regulation of secondary injury and re
covery, using graded doses of DNP.
Collectively, we observed age-dependent effects on the function of
isolated mitochondria after SCI and DNP treatment. In vivo, doseresponse DNP treatment produced age-divergent effect on ROS accu
mulation, neurodegeneration, and functional recovery at multiple time
points after SCI in 4- and 14-month old (MO) mice. Specifically, 14-MO
mice benefitted from DNP treatment while DNP worsened outcomes in
4-MO mice. Collective results demonstrate that age-associated changes
in mitochondrial function have profound effects on injury-induced
neurodegeneration and highlight the importance of age as a biological
variable in the treatment and progression of central nervous system
disorders.

age 4- and 14-MO were chosen as the most phylogenetically comparable
ages to represent the shift in clinical demographics from young adults to
middle age at time of SCI (Dutta and Sengupta, 2016; Semple et al.,
2013). Further, a 60 kdyn injury was chosen empirically based on pre
vious work demonstrating that a 50 kdyn injury is too mild to sustain
detectable functional deficits in 4-MO mice, while a 75 kdyn injury is too
severe in 14-MO mice, resulting in increased mortality and an inability
to weight support during objective functional analysis. Mice were
anesthetized using intraperitoneal (IP) injections of ketamine (100.0
mg/kg) and xylazine (10.0 mg/kg), and received analgesic (Buprenex
SR, 1.0 mg/kg day of surgery), antibiotic (Enrofloxacin, 5.0 mg/kg for 5
days), and saline (1.0 mL/day for 5 days) support following surgery. All
mice were group housed for the duration of the study on a 14 h light/10
h dark cycle. Manual bladder evacuations were performed 2×/day for
the duration of the study.
Mice were randomly assigned to receive DNP (Sigma Aldrich CO. St.
Louis, MO; 1.0-, 2.5-, or 5.0-mg/kg), or vehicle (1% dimethyl sulfoxide;
DMSO), which were delivered via intraperitoneal (IP) bolus injections
(10 μL per g body weight) 30 min post-injury then daily for up-to 7 days.
Stock 50.0 mg/mL concentrations of DNP were dissolved in DMSO and
diluted in sterile phosphate buffered saline (0.01 M; PBS) immediately
before use. Throughout the following three major experiments (1. Ex
vivo mitochondrial analyses, 2. 7-day survival, 3. 28-day survival) a total
of n = 4 4-MO mice, and n = 9 14-MO mice were lost due to premature
morbidity or mortality or surgical complications. Respectively for 4- and
14-MO mice, n = 1- and 2-mice died overnight after SCI; n = 2- and 5mice died under anesthesia for unknown reasons; n = 1- and 1-mice
were excluded based upon a priori exclusion criteria for abnormal
impact parameters indicative of a bone hit or spinal movement at the
time of injury; and n = 0- and n = 1-mice were euthanized two days prior
to the end of study due to a major open and untreatable skin wound; the
spinal cord from this mouse was included in histology and did not vary
from others in group. The cause of mortality remains unknown for the
three mice that died overnight after receiving SCI. Two of the three mice
received a 5.0-mg/kg dose of DNP, while the third received a 1.0-mg/kg
dose, therefore toxicity from DNP may be possible. All other mice
experiencing mortality under anesthesia died prior to delivery of DNP.
Supplementary Table 1 contains lists of final sample sizes used for all
groups in all outcomes.
2.2. Ex vivo mitochondrial response to DNP
Mitochondria were isolated as previously described (Brown et al.,
2004) from 4- and 14-MO sham, or SCI-treated mice at 3- and 7-days
post-injury (dpi). Briefly, mice were euthanized using CO2 followed by
rapid decapitation. A 7-mm section of cord surrounding the lesion was
quickly isolated and mechanically homogenized in respiration buffer.
Tissue suspension was centrifuged at 1300 g to pellet debris, followed by
collecting the supernatant and pelleting crude mitochondria at 13,000 g.
Crude mitochondrial extract was suspended in respiration buffer and
synaptic mitochondrial fractions were liberated using nitrogen
bombing. Crude mitochondria were standardized based on protein
content and evaluated for oxygen consumption rate (OCR) on the Sea
horse (Seahorse XFe96 Analyzer; Agilent Technologies, Inc.; Santa
Carla, CA) as previously described (Patel et al., 2009). The sensitivity of
mitochondria to uncoupling was performed using pre-loaded auto-in
jection ports to administer 1-, 10-, or 100-μM DNP in series and the
change in OCR was obtained. Next, to perform a mitochondrial stress
test, mitochondria were isolated from sham or vehicle-treated SCI-mice,
as well as SCI-mice treated with 1.0 mg/kg DNP for 3- or 7-dpi. All
mitochondrial experiments were initiated by treating wells with 5 mM
Pyruvate, 2.5 mM Malate, and 1.0 mM ADP to drive State III respiration.
Mitochondrial stress tests proceeded as previously described (Sauerbeck
et al., 2011), using sequential delivery of Pyruvate/Malate/ADP (State
III), Oligomycin (State IV), FCCP (State VCI), and Rotenone/Succinate
(State VCII) to test different respiratory states. Experiments were

2. Material and methods
2.1. Animals, surgical procedures, and DNP delivery
All procedures followed institutional and national guidelines for the
care and use of laboratory animals as approved by the University of
Kentucky’s Animal Care and Use Committee. Female C57/Bl6 mice of
age 4- (n = 63; Jackson Laboratories) and 14-months old (MO) (n = 67;
National Institute for Aging) received surgical laminectomy followed by
a 60 kdyn T9 contusion SCI (Infinite Horizons Impactor) as previously
described (Zhang et al., 2016), or laminectomy only (n = 12). Mice of
2
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performed using 2–3 technical replicates per biological sample (n = 3/
group) depending upon auto-injecting success.

throughout all measured sections.
Axon sprouting was analyzed within the lesion at 28-dpi using a
staining threshold to detect DAB labeled axon filaments. The average
proportion of positive labeled pixels to lesion area was analyzed in 3
sections surrounding the epicenter per animal and used for comparison
between groups.

2.3. Functional analysis
Prior to SCI all mice were acclimated to testing paradigms including
an open field for the Basso mouse scale (BMS; (Basso et al., 2006)) and
the horizontal ladder (Cummings et al., 2007). Functional abilities were
assessed after SCI using the BMS at 1-, 3-, 7-, 14-, 21-, and 28-dpi.
Horizontal ladder was tested prior to injury and at 28-dpi for animals
capable of performing at least coordinated stepping. This resulted in
exclusion of 2 vehicle-treated 14-MO mice from analysis for an inability
to step. To analyze horizontal ladder, video was captured from under
neath as mice traversed a small 1.0 m ladder containing evenly spaced
rungs. Misplaced hindlimb steps resulting in foot-slips beyond the plane
of rungs were analyzed from video acquisition. Two reviewers who were
blinded to experimental groups were used to assign BMS scores and one
reviewer counted foot-slips on the horizontal ladder.

2.4.3. Reactive nitrogen species accumulation
Reactive nitrogen species (RNS) damage was assessed at 7-dpi using
immunolabeling against 3-nitrotyrosine (3-NT; 06-284; 1:2000; Sigma
Aldrich CO., St. Louis, MO), as a measure of protein nitration (Carrico
et al., 2010). To analyze 3-NT labeling, tissue sections up to 1-mm
rostral and caudal to the epicenter were traced and a threshold was
created to exclude non-positively labeled pixels from analysis. A
threshold for determining positive pixel density was set based on tissue
containing no 3-NT labeling from a 4-MO mouse section. No 3-NT la
beling was performed at 28-dpi as increases in 3-NT have been reported
to return to near-baseline conditions before 14-dpi (Carrico et al., 2010).
2.4.4. Neuronal survival
Neuronal sparing was assessed using immunolabeling against
neuronal nuclei (NeuN; NBP1-77686; 1:4000; Novus Biologicals,
Centennial, CO). Neuron viability was determined by tracing around the
ventral horns of tissue sections and applying a particle counting algo
rithm available on the Halo software. Parameters were set to identify
neurons based on density, circularity, size, and contrast. Neuron counts
from every other section between 500 μm rostral and caudal to the
epicenter was summed and used to analyze 7-dpi tissue, and every
section between 500 μm rostral and caudal to the epicenter was summed
for 28-dpi tissue.

2.4. Histological outcomes
2.4.1. Tissue preparation
At 7- and 28-dpi, vehicle and DNP-treated mice were anesthetized
with a lethal dose of ketamine, exsanguinated using 0.1 M PBS, and
perfused using 4% formaldehyde (Thermo Fisher Scientific, Waltham,
MA). Spinal cord segments were collected, post-fixed in 4% formalde
hyde for 2 h at room temperature, incubated overnight in 0.2 M phos
phate buffer, then dehydrated with 30% sucrose (Sigma Aldrich CO., St.
Louis, MO) at 4 ◦ C. Spinal cords were placed side by side in cryomolds in
sets of 4–5 cords/block in Optimal Cutting Temperature Compound
(OCT), and frozen on dry ice. Spinal cords were arranged in a random
order while ensuring at least one cord per group was frozen in each
block. Sections were cut in the transverse plane at a 10-μm thickness and
mounted in serial order, with 100 μm between serial sections on a slide.
Prior to immunolabeling all slides were processed using heat-mediated
antigen retrieval in 0.1 M sodium citrate buffer (pH 6.0) at 80 ◦ C for
5 min.
Each set of immunolabeling, imaging, and analysis was performed
for all animals in a single cohort, using identical staining, imaging
acquisition, and analysis settings. Images were acquired using Zeiss
Axioscan (model Z1, Carl Zeiss AG., Oberkochen, GE) and analyzed
using Halo software (Indica Labs, Albuquerque, NM). Histology and
immunohistochemistry was performed by individuals blind to group
inclusion as follows.

2.5. Statistics
Statistical modeling was performed in collaboration with University
of Kentucky’s interdepartmental Applied Statistics Laboratory (ASL).
General linear models were created to determine the effects of age, dose,
and injury when appropriate. When comparing between ages was
appropriate two- or three-way analysis of variance (ANOVA) was used.
This includes analysis of ex vivo mitochondrial experiments, propor
tional area of 3-NT labeling, and horizontal ladder using two-way
ANOVA, as well as analysis of motor functions on BMS and BMS subscores using three-way ANOVA with repeated measures. Because spi
nal cord size increases with age, outcomes dependent on absolute tissue
area (sparing) and cell counts (neuron survival) were analyzed using
within age-group comparisons with one-way ANOVA or two-way
repeated measures ANOVA when appropriate. To directly compare
outcomes between ages, values of DNP treated groups were normalized
to mean values of within-age vehicle treated groups and treatment ef
fects were compared between ages using two-way ANOVA. Dunnett’s
pair-wise comparisons were made to limit analysis within ages and be
tween vehicle and DNP-treated groups. Sidak’s pair-wise comparisons
were used to compare between-group treatment effects when normal
ized to vehicle controls. During analysis of neuron counts at 7-dpi, a
single outlier was found using Grubbs’ analysis (value = 81; G = 1.737;
p < 0.05) in the 4-MO 5.0-mg/kg/day DNP treatment group and was
removed from analysis. No other outliers were identified. Statistical
support was obtained from ASL to analyze BMS and BMS sub-scores due
to the non-normal repeated measures nature of BMS sub-score data. BMS
score models adjusted for the Day 1 score and BMS sub-scores were
normalized by using a square root transformation of the change from
Day 3. BMS analyses were completed using SAS 9.4 (SAS Institute, Cary,
NC). All other analyses were completed using Prism v. 8.0 (Graphpad,
San Diego, CA). Animal numbers for in vivo experiments were estimated
by power analyses (1-β = 0.80; α = 0.05; one-way ANOVA) using
standard deviations from pilot studies, as well as estimated effects from
prior experiments in our lab investigating effects of age on treatment

2.4.2. Tissue sparing and axon sprouting
Slides were stained with eriochrome cyanine (EC; Sigma Aldrich CO.,
St. Louis, MO) for myelin and counterstained with fast red (nuclei) at 7dpi, or immunolabeled for axons using neurofilament 200 kD (1:2500;
NFH; Aves Labs Inc., Davis, CA) at 28-dpi. Immunolabeling was visu
alized using 3,3′ -diaminobenzidine (DAB; Vector Laboratories, Inc.,
Burlington, CA) as a chromogen. To analyze lesion areas, regions of
spared tissue were traced, and areas were obtained. Tissue was consid
ered spared based on macro structure morphology, evident by the
clearly stained presence of white matter, or gray matter containing
neurons and organized axonal architecture; tissue sections at the lesion
epicenter typically have no spared gray matter and only a small rim of
spared white matter. Spared tissue was assessed in each section to
identify the section containing the least amount of spared tissue, which
was used to define the lesion epicenter. All histological analyses were
performed with respect to this defined epicenter. Due to a dynamic
nature of lesion volumes at 7-dpi, the epicenter was used as a single
predictor of tissue sparing for purposes of identifying an optimal dose for
behavioral studies. At 28-dpi tissue sparing was analyzed every 100 μm
for 700 μm rostral and caudal to the lesion. Tissue sparing at the lesion
epicenter was compared between groups, as well as total sparing
3
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efficacy using antioxidant therapies (Zhang et al., 2019). For behavioral
outcomes n = 10 was predicted sufficient to power BMS analyses, while
n = 5 was estimated for histological tissue sparing. For ex vivo mito
chondrial experiments, routine use of n = 3 with 3 technical replications
has proven sufficient power in prior experiments from our group
(Yonutas et al., 2015).

indicative of an impaired capacity for energy production that can last at
least 3-, but not longer than 7-dpi.
Next we simulated mild uncoupling effects, which have been proven
safe for use in vivo (Jin et al., 2004; Maragos et al., 2003; Patel et al.,
2009), to determine if exposing mitochondria to low DNP doses
(1.0–10.0 μM) were age- or injury-dependent. A significant uncoupling
effect emerged at 10.0 μM DNP in mitochondria obtained from unin
jured mice at both 3- (F(2,4) = 24.86, p < 0.01; Fig. 1C) and 7-dpi (F =
(2,4) = 85.46, p < 0.005; Fig. 1D). After SCI however, only mitochondria
isolated from 14-MO injured-mice were responsive to low DNP doses at
3 dpi (p < 0.005)(Fig. 1). By 7 dpi, all mitochondrial populations
responded to low doses of DNP, confirming that injury induced deficits
were no longer detectable (p < 0.005)(Fig. 1). Here we observed that
mitochondrial responses to treatment after injury are age dependent and
that older mitochondria surprisingly maintain a higher sensitivity to
mitochondrial uncoupling. This age-dependent effect of isolated mito
chondria to mild uncoupling led us to hypothesize that an optimal DNP
dose for treating SCI in vivo may differ with age.

3. Results
3.1. Effects of mitochondrial uncoupling are age-dependent
We first set out to determine if age and SCI affect mitochondrial
function. Specifically, mitochondria were isolated from spinal cords
with or without (sham) moderate thoracic T9 contusion (60 kdyn) SCI.
OCR of isolated mitochondria was examined with the Seahorse bio
analyzer to determine effects of uncoupling using graded doses of DNP.
High DNP doses (100.0 μM) were used to completely uncouple mito
chondria, revealing significant SCI induced impairments in maximal
respiratory capacity at 3- (F(1,8) = 5.94, p < 0.05; Fig. 1A) but not 7-days
post-injury (dpi; F(1,8) = 0.66, p = 0.43; Fig. 1B). Surprisingly, age did
not exacerbate mitochondrial dysfunction after SCI when completely
uncoupled (Fig. 1). This SCI impairment of mitochondrial function is

Fig. 1. Ex vivo uncoupling of isolated mitochondria with DNP exert age-dependent effects. Mitochondria were isolated from 4- and 14-MO mice at 3- and 7-days post
sham (laminectomy) or spinal cord injury (SCI). Graded doses of DNP were administered to determine the efficiency of generating an uncoupling response. At 3- days
post-injury (DPI) maximum respiratory capacity was lower in mitochondria obtained from SCI- compared to sham-mice (A), no injury effect was detectable by 7-DPI
(B). All groups exhibited a significant uncoupling response upon administration of 10 μM DNP at 3-DPI (p < 0.005) except mitochondria obtained from 4-MO SCImice (C). This age-dependent response was ameliorated by 7-DPI where all groups exhibited a significant uncoupling response upon administration of 10 μM DNP (p
< 0.005; D). Analyzed using two-way ANOVA. Graphs represent mean ± SEM, n = 3/group. *p < 0.05, ***p < 0.005 vs vehicle (A, B) or vs baseline (C, D).
4
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3.2. A low dose of DNP is toxic to 4-MO- but protective to 14-MO-SCI
mice at 7-DPI

accumulation (F(1,30) = 5.31, p < 0.05; Fig. 2B). Further, we found that
the lowest DNP dose (1.0-mg/kg/day) significantly reduced 3-NT
accumulation only in 14-MO mice relative to vehicle controls (p <
0.05; Fig. 2B), demonstrating consistency with ex vivo analyses indi
cating that 14-MO injured-mitochondria are responsive to low DNP
doses (Fig. 1). DNP treatment was ineffective at reducing oxidative
damage in 4-MO mice regardless of dose (Fig. 2B). When results from 14and 4-MO mice were compared directly by normalizing to vehicle con
trols within each age, no significant effects were found (Fig. 2C).
Next, effects of DNP treatment on neuron survival and tissue sparing
were assessed within each age. For neuron sparing, 14-MO SCI mice
treated with DNP displayed no overall effects (F(3,15) = 2.05, p = 0.15;
Fig. 3B). Higher doses trended towards neuron toxicity but did not reach
significance (p = 0.14; Fig. 3B). In contrast, spinal cords from 4-MO mice
treated with DNP displayed an acute toxic response apparent through a
significant loss of neurons surrounding the lesion (F(3,12) = 9.16, p <
0.005) at all DNP doses (p < 0.05; Fig. 3B). There were dose-dependent
differences in tissue sparing in 14-MO SCI mice (F(3,16) = 2.88, p = 0.06;
Fig. 4B) with the 1.0-mg/kg/day dose varying significantly from vehicle
(Dunnett’s pairwise comparison, p = 0.05). There was no effect of higher
DNP doses on tissue sparing in 14-MO mice (p = 0.92), and no effects on
spared tissue were found in 4-MO mice (F(3,14) = 1.21, p = 0.34; Fig. 4B).
Comparing the absolute values of neuron survival and tissue sparing

To determine if age-dependent uncoupling persists in vivo after SCI,
we treated 4- and 14-MO SCI mice with graded doses of DNP for 7-dpi
and examined outcomes associated with mitochondrial dysfunction:
oxidative damage, neuron survival, and tissue sparing. Previous work
from our lab has identified the greatest age-dependent accumulation of
oxidative damage at 7-dpi (Zhang et al., 2016, 2015). Further, we found
that 14-MO mice experience greater loss of tissue surrounding SCI le
sions associated with this age-dependent increase in ROS (Zhang et al.,
2019, 2016, 2015). For mid-thoracic SCI, tissue sparing surrounding the
lesion strongly correlates to functional outcomes and therefore was
investigated as a merit to an overall treatment effect of DNP (Basso et al.,
1996).
To delineate the contribution of mitochondrial-derived ROS to
exacerbated tissue loss with age, we evaluated a dose-dependent
response of mild-uncoupling using DNP for 7-dpi. DNP doses were
chosen in accordance with prior literature citing a therapeutically
effective range from 1.0- to 5.0-mg/kg in young rodents (Maragos et al.,
2003; Patel et al., 2009). Consistent with our previous work finding
increased ROS damage (4-HNE) in 14- compared to 4-MO mice at 7 dpi
(Zhang et al., 2016), here we found an age-dependent increase in 3-NT

Fig. 2. The biomarker of reactive oxygen
species production, 3-NT, is reduced in 14MO mice treated with DNP at 7 days after
spinal cord injury. DNP was provided at 1.0-,
2.5-, or 5.0-mg/kg/day for 7 days to 4- and
14-MO mice after SCI to determine the ef
fects of uncoupling on accumulation of
oxidative stress. Immunohistochemistry was
performed to label nitrotyrosine (3-NT) ad
ducts that are indicative of upstream reac
tive oxygen species production. The 3-NT
labeled tissue surrounding the lesion was
analyzed as a percentage of the total cross
sectional area of the cord. Images of repre
sentative samples 500 μm away from the
lesion epicenter (A) reveal a significant in
crease in 3-NT expression in 14-MO mice
after SCI (p < 0.05; B). A 1.0 mg/kg/day
dose of DNP significantly reduced 3-NT
accumulation only in 14-MO mice after SCI
(p < 0.05; B). When compared to vehicletreated mice, no significant differences
were found in a treatment effect with DNP
between 4- and 14-MO mice (p = 0.09; C).
Scale bar represents 500 μm. Analyzed using
two-way ANOVA. Graphs represent mean ±
SEM, n = 3-5/group. *p < 0.05.
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Fig. 3. DNP exerts toxic effects on neuron survival in 4-MO mice at 7 days after spinal cord injury. Tissue obtained from mice at 7-DPI was analyzed for effects of
DNP on neuron survival. Images of representative samples taken at 500 μm away from the lesion epicenter (A) demonstrate a significant loss of neurons with all DNP
doses in 4- but not 14-MO mice (p < 0.05 for 1.0- and p < 0.005 for 2.5- and 5.0-mg/kg; B). When compared to vehicle-treated mice, no differences were found in a
treatment effect with DNP between 4- and 14-MO mice (p = 0.08; C). Scale bars represent 500 μm. Boxes represent analysis regions over the ventral horns, and
enlarged images. Arrows point to the central canal. Analyzed using one-way ANOVA for each age (B) or two-way ANOVA (C). Graphs represent mean ± SEM, n = 35/group. *p < 0.05, ***p < 0.005 vs. vehicle control.
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Fig. 4. DNP exerts age-divergent effects on
tissue sparing at 7 days after spinal cord
injury. The extent of tissue sparing was
assessed at 7-DPI after treatment with DNP.
Images of representative samples of lesion
epicenters (A) demonstrate that treatment
with 1.0-mg/kg/day DNP spared tissue in
14- but not 4-MO mice treated (p < 0.05; B).
When compared to same age vehicle-treated
groups, the 1.0- and 2.5-mg/kg/day DNP
doses resulted in significant age divergent
responses by reducing tissue sparing in 4MO SCI mice and preserving tissue in 14MO SCI mice (C). Scale bars represent 500
μm. Analyzed using one-way ANOVA for
each age (B) or two-way ANOVA (C). Graphs
represent mean ± SEM, n = 3–5/group. *p
< 0.05, **p < 0.01, ***p < 0.001.

between 4- and 14-MO mice is technically inappropriate because the
spinal cord size increases with musculoskeletal maturity over the first
7–8 months of age (Quinn, 2005). This can make an increased absolute
area of spared tissue in 14-MO, relative to 4-MO mice, proportionally
less compared to pre-injury values. Comparing tissue sparing between
ages is therefore compromised due to inherent size differences of the
spinal cord. An apparent increase in neurons surrounding the lesion in
14-MO mice was, however, unexpected. We do not yet know if this is a
biological response or a technical artifact similar what was described for
tissue sparing, however, this effect was reproduced at 28-DPI and can be
found below (Fig. 6).
In consideration of the technical limitations of directly comparing
effects of DNP on neuron survival and tissue sparing between ages, we
normalized values to age-matched vehicle-treated controls. We observed
no significant effects (F(2,19) = 3.38, p = 0.08; Fig. 3C) of age on neuron
toxicity but did observe a significant age-divergent response to DNP
treatment in spared tissue surrounding the lesion (F(1,21) = 13.72, p <
0.001; Fig. 4C). Post hoc analyses revealed a significant increase in tissue
sparing in 14- compared to 4-MO mice treated with 1.0- (p < 0.01) and
2.5-mg/kg/day DNP (p < 0.05) relative to their respective vehicletreated controls (Fig. 4C). Together, these data support our ex vivo
findings of mitochondria from 14-MO SCI-mice being more responsive
to mild uncoupling. Further, our data demonstrate that age has a pro
found effect on mitochondria-mediated neurodegeneration as indicated
by opposite treatment effects in 14- and 4-MO SCI-mice.

4. DNP maintains age-divergent effects at 28-DPI
Due to fluctuating events acutely within the injured microenviron
ment, recovery from injury can take weeks to stabilize (Basso et al.,
2006; Detloff et al., 2012; Silva et al., 2014). Previously we reported that
acute mitigation of ROS production in 14-MO SCI-mice leads to
improved and stabilized recovery by 3–4 weeks post-injury (Zhang et al.,
2019). Therefore, we examined functional and anatomical recovery for
28-dpi to determine long-term effects of DNP treatment on SCI neuro
pathology and functional outcomes. Because data obtained at 7-dpi was
inconsistent with prior literature that suggests a 5.0-mg/kg/day dose of
DNP is most protective (Jin et al., 2004; Patel et al., 2009), we utilized
both a 5.0- and 1.0-mg/kg/day dose that appeared most efficacious in
14-MO mice.
As reported previously, we observed a significant effect of age on
locomotor outcomes after SCI with 14-MO mice having significantly
impaired over ground (BMS; F(1,49) = 15.18, p < 0.0005; Fig. 5A) and
proprioceptive (horizontal ladder; F(2,47) = 12.21, p < 0.001; Fig. 5C)
locomotor function relative to 4-MO mice (Zhang et al., 2019, 2016,
2015). There were no interactions among treatment and age on the
horizontal ladder. A significant three-way interaction (F(8,199) = 2.01, p
< 0.05) was found for motor recovery on open field BMS analysis,
suggesting a differential response to DNP with age (Fig. 5A). Specif
ically, 14-MO mice treated with either 1.0- or 5.0-mg/kg/day had sig
nificant improvements in overt locomotion (BMS scores; p < 0.05)
7
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Fig. 5. DNP exerts age-divergent effects on motor functions after spinal cord injury. DNP treatment (1.0-mg/kg/day for 7 days after injury) significantly reduced
motor function by 28-DPI in 4-MO SCI mice (p < 0.005) but improved recovery in 14-MO SCI mice (p < 0.05) when analyzed with BMS motor score (A,D). A
significant improvement in BMS scores was also observed in 14-MO, but not 4-MO, mice treated with 5.0-mg/kg/day (p < 0.05; A). Similar effects were observed for
BMS sub-scores in 4- but not 14-MO mice by 28-DPI (p < 0.01; B). A main effect of age was observed for foot-slips on horizontal ladder (p < 0.005) but no effects were
found for treatment with DNP (C). Age-divergent effects were apparent at 28-DPI on BMS scores when compared to age-matched vehicle-treated mice at both 1.0- (p
< 0.005) and 5.0 mg/kg/day doses (p < 0.05; D). Analyzed using Three-way ANOVA with repeated measures (A, B) or two-way ANOVA (C, D). Graphs represent
mean ± SEM, n = 8-10/group for BMS and BMS sub-score and n = 6–10/group for horizontal ladder. *p < 0.05, **p < 0.01, ***p < 0.005, vs same day
vehicle controls.

compared to vehicle treated mice. In contrast, 4-MO mice treated with
1.0-mg/kg/day DNP demonstrated toxicity apparent through signifi
cantly worse motor recovery by 21-dpi in measures of both overt loco
motion (BMS; p < 0.005) and finer details of hindlimb and locomotor

function (BMS sub-scores; p = 0.01; Fig. 5B). Similar to data obtained at
7-dpi, significant age-divergent effects were apparent in BMS scores
(F(1,34) = 10.44, p < 0.01) for mice treated with 1.0-mg/kg/day of DNP
(p < 0.005) after normalizing values to age-matched vehicle-treated
8
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mice (Fig. 5D). Specifically, on average 14-MO SCI-mice improved by
>25% relative to vehicle-treated mice, while locomotor function in 4MO SCI mice decreased by ~25% (Fig. 5D).
With regards to long term neurodegenerative outcomes, no signifi
cant effects were detected for treatment on neuron survival (4-MO
F(2,26) = 0.59, p = 0.55; 14-MO F(2,24) = 1.56, p = 0.23; Fig. 6A, B), or
axon sprouting at 28-dpi (4-MO F(2,26) = 3.17, p = 0.058; 14-MO F(2,24)
= 2.22, p = 0.12)(Fig. 6C, D). Not observing a similar toxic effect on
neurons at 28-dpi, as we did at 7-dpi, suggests that DNP accelerated the
death of neurons that were likely going to experience a delayed death
after injury alone. However, locomotor recovery after SCI is more
closely associated with the extent of tissue sparing surrounding the
lesion, particularly at the lesion epicenter (Basso et al., 1995). Consistent
with our observations of age-divergent effects of DNP treatment on lo
comotor function, we observed that DNP exerts an overall toxic effect on

tissue sparing at the lesion epicenter in 4- (F(2,26) = 3.804, p < 0.05) but
not 14-MO SCI-mice (F(2,24) = 0.11, p = 0.89; Fig. 7B). Specifically, DNP
exacerbated tissue loss at the lesion epicenter in 4-MO mice treated with
1.0- (p < 0.05), but not 5.0-mg/kg/day (p < 0.15; Fig. 7B), as well as, an
overall loss of tissue extending 700 μm rostral and caudal to the
epicenter (p < 0.05)(Fig. 7). No differences were found for the rostralcaudal length of lesion (4-MO F(2,26) = 0.46, p = 0.63; 14-MO F(2,24)
= 1.46, p = 0.25; Fig. 7C), or when evaluating tissue sparing with
repeated measures over a 7 mm span of sectioned tissue (4-MO F(2,26) =
1.464, p = 0.25; 14-MO F(2,24) = 0.27, p = 0.76) in either age (Fig. 7E).
Comparing spared tissue in DNP-treated mice relative to vehicletreated mice between ages revealed that DNP exerts an overall signifi
cant age-dependent toxicity to 4-MO mice (F(1,33) = 8.79, p < 0.01), with
~25% decrease in tissue sparing with each dose (1.0-mg/kg/day, p =
0.07; 5.0-mg/kg/day, p = 0.09) (Fig. 7D). DNP treatment did not vary

Fig. 6. DNP does not exert significant effects on neuron survival or axon sprouting at 28 days after spinal cord injury. Toxic effects of DNP on neurons were
normalized by 28-DPI, similarly no significant effects were found for axon sprouting. Images of representative samples obtained at 500 μm rostral to the lesion
epicenter (A) or at the lesion epicenter (C) demonstrate no differences in neuron survival (B) or axon sprouting in the lesion (D). Scale bars represent 100 μm (C) and
500 μm (D). Analyzed using one-way ANOVA for each age. Graphs represent mean ± SEM, n = 8–10/group.
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Fig. 7. DNP reduces tissue sparing in 4-MO mice at 28 days after spinal cord injury. Lesion sizes stabilize by 28-DPI, which revealed a sustained toxic effect of DNP on
tissue preservation to 4-MO mice, with no effects occurring in 14-MO mice. Lesion epicenter images representative of group means (A) demonstrate a significant
reduction in tissue sparing in 4- but not 14-MO SCI mice treated with 1.0-mg/kg/day (for 7 days after SCI) of DNP (B). Treating SCI mice with 1.0-mg/kg/day of DNP
reduced spared tissue spanning the lesion up to 700 μM rostral and caudal to the epicenter in 4-MO animals compared to vehicle-treated controls (p < 0.05). Overall
effects of DNP treatment exerted an age-dependent toxic response that reduced tissue sparing significantly in 4-MO mice with no effects on 14-MO mice (p < 0.01; D).
Scale bars represent 500 μm. Analyzed using one-way ANOVA for each age (B,C), two-way ANOVA (D), or two-way ANOVA with repeated measures for each age (E).
Graphs represent mean ± SEM, n = 8–10/group. *p < 0.05, **p < 0.01.

significantly from vehicle controls in 14-MO SCI mice. Together with our
data from 7-dpi, our results show that acute age differences in mito
chondrial responses to injury manifest in long term functional deficits
and neurodegeneration in an age-divergent manner.

complex I capacity may appear detrimental at first, this may result in
less produced ROS from a lowered metabolic activity. This would be
consistent with our findings that 1.0 mg/kg/day DNP attenuated 3-NT
accumulation in 14-MO mice.

5. In vivo DNP significantly reduces complex I mediated
respiration in aged mice

6. Discussion
As life expectancies increase, age-associated declines in cellular
processes play an increasing role in the pathophysiology of neurode
generative conditions. Interactions between how age affects tissue re
sponses in injury and disease will likely have unique consequences on
therapeutic strategies. Without considering age as a variable in clinical
or pre-clinical studies, it will be difficult to predict how biological pro
cesses respond to insults across the lifespan. Neurotrauma is specifically
affected by age, as traumatic brain injury (TBI) exacerbates ageassociated neurodegeneration (i.e. chronic traumatic encephalopathy)
and the demographic of spinal cord injury (SCI) is shifting to older in
dividuals sustaining injuries.
The major aim of this study was to determine how aging effects
mitochondrial regulation of neurodegeneration in a mouse model of SCI.
We found that mild mitochondrial uncoupling exerts age-divergent ef
fects, ultimately resulting in improvements in function in 14-MO (month
old) SCI-mice but further impairing function of 4-MO SCI-mice. Specif
ically, we observed that after SCI, age increases the sensitivity of isolated
mitochondria to ex vivo uncoupling using DNP. In vivo, we observed that
DNP reduced neuron and white matter survival in 4-MO SCI-mice, but
the same dose had protective effects in 14-MO SCI-mice and reduced
protein nitration. This age-divergent response to DNP manifested as
long-term impairments in tissue preservation and locomotor function in

Having replicated age-divergent effects of treating SCI-mice with 1.0
mg/kg DNP at both 7- and 28-dpi, we sought to investigate how in vivo
DNP treatment affects mitochondrial functions. We isolated mitochon
dria from 4- and 14-MO mice receiving either sham-, SCI + vehicle, or
SCI + 1.0 mg/kg/day DNP for either 3- or 7-days after SCI. Seahorse was
used to determine respiratory efficiency in State III and State IV respi
ration, as well as to test for complex I and II mediated electron transport.
ATP-linked respiration was calculated by subtracting State III from State
IV respiration to control for non-respiratory oxygen consumption.
Coupling efficiency was also calculated using respiratory control ratios
(RCR; State III/State IV).
While no significant interactions were found, effects of DNP on
mitochondrial functions persisted to display an age divergent trend at 3DPI, only in an unexpected direction. DNP appeared to further exacer
bate SCI-induced mitochondrial deficits in 14-MO mice, and signifi
cantly impaired complex I mediated electron transport compared to
sham controls (p < 0.05; Fig. 8A). No other significant effects were found
at 3-dpi (Fig. 8A–C) and no injury or treatment effects were observed at
7-dpi (Fig. 8D–F), however, ATP linked-respiration was decreased as a
main effect of age as previously reported (F(1,12) = 4.97, p < 0.05;
Fig. 8D; (Yonutas et al., 2015)). While the implications of a reduced
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Fig. 8. DNP lowers complex I-mediated electron transport with a preserved coupling efficiency in 14-MO mitochondria at 3-DPI. Mitochondria were isolated from
mice receiving sham-, SCI-, and SCI + 1.0 mg/kg/day DNP at 3- (A–C) and 7-DPI (D–F), and evaluated for bioenergetic capacity using a mitochondrial stress test on
Seahorse. The difference between mitochondrial state III and IV was used to evaluate ATP-linked respiration (B, E) and the ratio was used to calculate RCR as a
measure of coupling efficiency (C, F). Complex I and II mediated electron transport were determined during State V respiration. DNP significantly impaired complex I
mediated electron transport relative to sham-controls in 14-MO mice (p < 0.05), with SCI-only exerting an insignificant intermediate effect (p = 0.26 vs sham). DNP
exerted insignificant trends towards an overall reduction in oxygen consumption and ATP-linked respiration further away from sham values relative to SCI-only at 3DPI in 14-MO mice, however, DNP did not further reduce RCR coupling efficiency. DNP treatment or SCI-alone exerted no significant effects at 7-DPI, but main effects
of age reduced ATP-linked respiration (p < 0.05). Each outcome was analyzed using two-way ANOVA with Tukey’s post hoc used for pairwise comparisons within
each age. Graphs represent mean ± SEM, n = 3/group.

4-MO SCI-mice with contrasting improvements in 14-MO mice. Finally,
in vivo treatment with DNP reduced complex I mediated electron
transport only in isolated 14-MO injured mitochondria, but preserved
coupling efficiency (RCR) relative to mice receiving SCI and vehicle. A
decrease in respiratory capacity when RCR is preserved can be indica
tive of lower global electron transport activity. Under these conditions’

mitochondria may reduce ROS production, which might underly why
DNP decreased 3-NT accumulation only in 14-MO mice. Our findings
point to the endogenous regulation of mitochondrial function as an
important mediator of recovery at younger ages that shifts towards a
contributor of pathology with advanced age. Further, our findings
emphasize a need to consider the age dependence of therapeutic
11
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interventions targeting SCI as well as various other neurodegenerative
conditions.
As knowledge of neurological disorders advance, diagnostic capa
bilities are becoming available at earlier stages of disease. Moving for
ward it will be of vital importance to consider age at the time of
treatment as a variable in our efforts to advance personalized medicine.
If similar interactions exist in other neurological conditions or with
different drugs, our data indicate that intervention at too early an age
can possibly accelerate disease progression. Researchers often utilize
accelerated animal models of disease such as the 3xTg mouse model of
Alzheimer’s disease, the R6/2 model of Huntington’s disease, or the 6hydroxydopamine model of Parkinson’s disease to understand neuro
logical conditions of aging (Hernandez-Baltazar et al., 2017; Li et al.,
2005; Sterniczuk et al., 2010). Our findings indicate that interactions
between an animals age and induced onset of disease may confound
interpretations of how mitochondria contribute to pathogenesis and
challenge the translatability of treatment strategies into clinical pop
ulations. In particular, discontinuities in ages used for pre-clinical stroke
studies compared to patients enrolled in clinical trials is increasingly
implicated in the widespread failure to translate therapies (Ay et al.,
2005; Badan et al., 2003; Cheng et al., 2009; Herson and Traystman,
2014; Pennypacker et al., 2017).
Within the field of neurotrauma our findings have far reaching im
plications. First, clinical demographics are progressing towards an
increased average age at time of SCI (NSCISC, 2013; Toda et al., 2018).
Yet, when evaluating the therapeutic potential of drugs in clinical
populations, age is often not considered as a variable underlying treat
ment efficacy. To date the only drug used to treat SCI is methylpred
nisolone, which functions predominately to suppress injury-induced
inflammation (Bracken et al., 1990, 1997). Efficacy of methylprednis
olone as a treatment for SCI has been under scrutiny and is falling out of
use due to complications associated with immune suppression. How
ever, advancements in rodent models of SCI have recently demonstrated
that treatments targeting ROS and inflammation may exert effects in
older rodents even when little effects are found at younger ages (Zhang
et al., 2019). This should merit re-evaluation of clinical data to deter
mine if the effectiveness of previously investigated drugs targeting ROS
exert improved efficacy with age (Stewart et al., 2019).
Given the resilience of younger individuals to neurological recovery
after trauma or disease, one would predict that an increased age at time
of injury would decrease treatment-mediated recovery. Unexpectedly, in
the current study, we found that age increased the sensitivity of isolated
injured mitochondria to ex vivo uncoupling with DNP, and found that
DNP exerts reciprocal effects to 4- and 14-MO mice after SCI. As we and
others have demonstrated, this may be due to ROS playing a larger role
in the pathophysiology of SCI with advanced age (von Leden et al., 2017;
Zhang et al., 2016). Due to the juxtaposing nature of mitochondrial
uncoupling by decreasing both ROS and ATP, what can be derived from
our work is that net contributions of mitochondrial function after SCI
progress towards a more pathological role with advancing age in part by
increasing free radical damage.
The mechanisms underlying the age-divergent effects found in this
study remain unknown. While cellular toxicity caused by decreased ATP
is possible, there is little evidence to suggest that mild uncoupling using
doses in this study would exert a major energy crisis. Rodent studies in
Huntington’s disease have used repeated dosing of DNP at 1.0 mg/kg/
day and found beneficial effects on the progression of the disease (Wu
et al., 2017); however, repeated dosing at 5.0 mg/kg did inevitably
result in toxic effects. This contrasts our study that demonstrated the
higher 5.0 mg/kg dose of DNP was less toxic than a lower 1.0 mg/kg
dose to 4-MO mice. Since DNP uncouples mitochondria in a dosedependent manner (Fig. 1), and a higher dose of DNP was less toxic in
our study, there are likely alternative mechanisms to a major energy
crisis that can explain the observed age-divergent trends.
One possible mechanism to explain our age-divergent effects may be
attributed to a decreased calcium uptake by mitochondria treated with

DNP (Sedlic et al., 2010). Glutamate-induced excitotoxicity occurring
after SCI induces high cellular influx of Ca2+ which is buffered by
mitochondria. At a certain Ca2+ influx threshold, the mitochondrial
permeability transition pore (mPTP) opens and floods the cytoplasm
with Ca2+, collapses the membrane potential, and expels NAD(H)
(Nicholls and Ward, 2000). Whereas transient opening of the mPTP can
be a physiological regulator of ROS production, sustained opening of the
mPTP swells the outer mitochondrial membrane, causing release of
cytochrome C into the cytoplasm and initiation of apoptotic cascades
(Huang et al., 2001). Our data found that older and injured mitochon
dria uncouple at lower DNP doses, which may confer a greater resistance
to mitochondrial Ca2+ uptake in 14-MO SCI-mice. Under these circum
stances, any modest toxicity associated with decreased ATP production
may be counter-balanced by a therapeutic capacity to reduce Ca2+ up
take and limit opening of the mPTP.
A decreased Ca2+ uptake by mitochondria can result in greater
cytosolic Ca2+ and lead to downstream activation of transcriptional
activity. Additionally, while Ca2+-induced gene regulation is probable
following DNP administration, effects of DNP have been affiliated with
upregulated cAMP-associated genes independent of Ca2+ signaling
(Sebollela et al., 2010). Effects found by Sebollela et al. (2010) are
particularly intriguing because the in vitro DNP doses used were low
enough to not impact mitochondrial oxygen consumption. This dem
onstrates that DNP doses in the mild-uncoupling range can exert offtarget effects. Due to the function of DNP as being both a weak acid
and very membrane permeable, it is likely that other organelles that
function on pH gradients, such as lysosomes, may be affected by mito
chondrial uncouplers (Andres et al., 1996). In the context of aging,
lysosome dysfunction has been affiliated with detrimental autophagic
abilities (Mattson and Arumugam, 2018). If DNP does exert effects on
lysosomal function, it may be possible for sustained delivery of DNP to
exert age-divergent cellular effects from mechanisms independent of the
mitochondria, however this has not been examined.
Our results indicating that DNP exerts toxic effects to 4-MO mice
contrasts with our previous work demonstrating therapeutic effects in
young rats after SCI (Jin et al., 2004; Patel et al., 2009). Besides use of a
different species, the most notable methodological discrepancies be
tween this work and previous reports were in dosing paradigms. Spe
cifically, our previous work with DNP performed in rat models of SCI
utilized either a single pre-treatment or a single acute dose (Jin et al.,
2004; Patel et al., 2009), whereas this study utilized daily doses for 1week post-injury with a 30-min delay from time of injury to adminis
tration. DNP has been administered daily for extended periods of time as
a treatment in other animal models of neurodegenerative diseases with
improved outcomes found after TBI, Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease, as well as promoting overall longevity of
life (Caldeira da Silva et al., 2008; De Felice and Ferreira, 2006; Hubbard
et al., 2018; Lee et al., 2017; Wu et al., 2017). This led us to believe that
multiple doses may exert additional protective effects following SCI,
however this may not have been the case for younger 4-MO mice. It
remains critical for future studies to evaluate the effects of sustained,
compared to acute, mitochondrial uncoupling on recovery from neuro
trauma to better elucidate the role of mitochondria on both injury and
repair. Further, our data highlights potential metabolic differences with
age that change the net effects of DNP, which merits further investiga
tion into the pharmacodynamic interaction between age and bioavailability within the cord.
Finally, it is important to note that mitochondrial function is
differentially regulated spatially within the nervous system (Sullivan
et al., 2004; Yonutas et al., 2015), temporally following injury (Thawer
et al., 2013), with cellular specificity (Fecher et al., 2019; Hubbard et al.,
2019; Patel et al., 2009), and potentially in a species-specific manner.
Not all cells are affected the same by age which could result in a dif
ferential response to DNP in a cell- and aging-dependent interaction. For
example, increasing evidence indicates that mitochondrial function
regulates macrophage and microglia phenotype (Devanney et al., 2020)
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and we observed that the macrophage response to SCI increases with age
(Zhang et al., 2019). The extent to which age and mitochondrial func
tion of macrophages contributes to the current results requires further
investigation. Further, aging alone has been attributed to an increase in
mitochondrial-derived ROS that is dependent upon cell type and may
differentially be affected by DNP. Even within a species subtle genetic
differences can exert large effects on mitochondrial function (Gameiro
et al., 2013; Ripoll et al., 2012). What can be concluded from the current
study is that the influence of mitochondrial function following SCI also
depends on age. Understanding how age effects the spatial, temporal,
cellular, and species specificity of mitochondrial functions remains to be
elucidated and may be essential for successful translation of
mitochondrial-targeting therapeutic strategies.
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